Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEP-701 in hormone-refractory prostate cancer
NCT00081601Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Mar 2004
- Primary completion
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lestaurtinib in prostate cancer (PCa), sponsored by Cephalon, Inc. Primary endpoint: Serological Prostate Specific Antigen Response Rate at 85 days. Started Mar 2004; status: completed.
02
Drugs
lestaurtinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00081601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081601.